Results 71 to 80 of about 14,435 (170)

Letter to the Editor Regarding “Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase”

Cancer Medicine, Volume 15, Issue 10, October 2026.
Maria Mazzitelli, Pierluigi Del Vecchio, Jon Salmanton‐García, Antonella Cingolani, Livio Pagano, Carlo Torti   +5 more
wiley   +1 more source

Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
A highly integrated workflow combining various computational, biophysical, and biochemical methods guides the discovery and characterization of an original naphthol‐based scaffold with inhibitory activity against the main protease of SARS‐CoV‐2 and demonstrates the efficiency of a sophisticated, open‐access consensus ranking protocol for virtual ...
Ifigeneia Akrani, Haifa El Kilani, Franck Touret, Sophia Kouvali, Veronika Gourni, Aggeliki Tsoka, Joulia K. Tsetis, Constantinos Vorgias, Rolf Hilgenfeld, Ioannis K. Kostakis, Vassilios Myrianthopoulos, Emmanuel Mikros   +11 more
wiley   +1 more source

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Journal of Cardiothoracic Surgery
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients.
Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang, Yi-Hsi Wang   +9 more
doaj   +1 more source

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Nature Communications
Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection.
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung   +6 more
doaj   +1 more source

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions

Cardiology Discovery
. With the increasing use of nirmatrelvir-ritonavir in older COVID-19 patients, adverse drug reactions due to drug-drug interactions have become more frequent.
Zhiqing Fu, Yan Guo, Shuai Li, Yang Shi, Hanjia Gao   +4 more
doaj   +1 more source

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice

European Cardiology Review
Cardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted.
Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, Eva Agostina Montuori, Luciano Pacelli   +4 more
doaj   +1 more source

Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients:A target trial emulation study [PDF]

Background Molnupiravir and nirmatrelvir-ritonavir have demonstrated efficacy in reducing hospitalization and mortality among unvaccinated, high-risk COVID-19 outpatients. However, their impact on hospitalized adults remains unclear.
Boyuan Wang, Wang, Boyuan, Wong, Ian Chi Kei, Wing Ming Chu, Chan, Esther Wai Yin, Kwok Yung Yuen, Eric Yuk Fai Wan, Ian Chi Kei Wong, Yuen, Kwok Yung, Choi, Ming Hong, Esther Wai Yin Chan, Chu, Wing Ming, Ivan Fan Ngai Hung, Xu, Yahui, Yahui Xu, Ming Hong Choi, Wan, Eric Yuk Fai, Anthony Raymond Tam, Hung, Ivan Fan Ngai, Tam, Anthony Raymond   +19 more
core   +1 more source

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19

Frontiers in Pharmacology
Patients with systemic autoimmune rheumatic diseases are at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and effective antiviral treatments including nirmatrelvir/ritonavir can improve their outcomes.
Wei Zhang, Wei Zhang, Xingguo Zhang, Xingguo Zhang, Jinming Han, Wen Zhang, Jiarui Xu, Jiarui Xu, Xin Zhang, Hongjun Bian, Chong Meng, Deya Shang, Yi Zhou, Dawei Wang, Baobao Feng, Baobao Feng   +15 more
doaj   +1 more source